Grant: Doctoral Research Award: Canada Graduate Scholarships
Institut de recherches cliniques de Montréal
$105,000.00
Regulation of anti-tumor T cell responses by Hippo pathway kinase Mst1
EF 2021-22
Résumé
Upon failure of standard cancer treatments such as radiotherapy and chemotherapy, alternative treatments are essential to cure cancer. Cancer immunotherapy, which is based on increasing the ability of the immune system to fight cancer, has become a promising option to treat cancer. Although the success rates of most immunotherapies remain limited, the scientific community has gathered to study patients that respond positively to immunotherapy. One main insight is that a durable cure of cancer relies on the generation of "long-lasting killer T cells", a group of elite immune cells which can persist and protect against cancer for a longer period. Recently, I collected preliminary evidence that a protein termed "Mst1" is a negative regulator of long-lasting killer T cells and that Mst1 inhibition can empower the immune system to kill cancer cells. My goal is to understand how Mst1 shapes the nature of T cells and whether some other proteins can be exploited to increase the number of long-lasting killer T cells and eliminate tumors. The research outcomes of my project may provide more effective treatment options to people suffering from cancer by improving current immunotherapies.
Programme
Doctoral Research Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Quebec, Canada
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
458663
Name
Bouchard Antoine
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Regulation of anti-tumor T cell responses by Hippo pathway kinase Mst1
Programtype2
Studentship Programs
Orgnameinp2
Institut de recherches cliniques de Montréal
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Research Award: Canada Graduate Scholarships
Keyworddelim
Anti-Tumor T Cell Immunity; Cd8 T Stem-Cell Memory (Tscm); Flow Cytometry And Phosphoflow; Hippo Signaling; Immune Checkpoint Blockade; Immunotherapy; Melanoma Tumor Transplantation Model; Single-Cell Rna Sequencing; T Regulatory Cells (Tregs); Wnt Signaling
Abstract
Upon failure of standard cancer treatments such as radiotherapy and chemotherapy, alternative treatments are essential to cure cancer. Cancer immunotherapy, which is based on increasing the ability of the immune system to fight cancer, has become a promising option to treat cancer. Although the success rates of most immunotherapies remain limited, the scientific community has gathered to study patients that respond positively to immunotherapy. One main insight is that a durable cure of cancer relies on the generation of "long-lasting killer T cells", a group of elite immune cells which can persist and protect against cancer for a longer period. Recently, I collected preliminary evidence that a protein termed "Mst1" is a negative regulator of long-lasting killer T cells and that Mst1 inhibition can empower the immune system to kill cancer cells. My goal is to understand how Mst1 shapes the nature of T cells and whether some other proteins can be exploited to increase the number of long-lasting killer T cells and eliminate tumors. The research outcomes of my project may provide more effective treatment options to people suffering from cancer by improving current immunotherapies.
Competitiondate
202111
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Bouchard, Antoine
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~